Expertise in
25
conditions

Dr. Hani L. Ashamalla

Radiation Oncology
NewYork-Presbyterian Brooklyn Methodist Hospital
506 6th St, 
Brooklyn, NY 
Offers Telehealth
Expertise in
25
conditions
NewYork-Presbyterian Brooklyn Methodist Hospital
506 6th St, 
Brooklyn, NY 

Overview

Hani Ashamalla is a Radiation Oncologist practicing medicine in Brooklyn, New York.

Dr. Ashamalla is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Prostatectomy.

He is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 15 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

NewYork-Presbyterian Brooklyn Methodist Hospital
506 6th St, Brooklyn, NY 11215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2026
Intervention Type: Radiation
Study Phase: Phase 3
Accelerated Radiation Therapy (ART) To The Breast And Nodal Stations After Neo-Adjuvant Systemic Therapy And Surgery: A Feasibility Study
Accelerated Radiation Therapy (ART) To The Breast And Nodal Stations After Neo-Adjuvant Systemic Therapy And Surgery: A Feasibility Study
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
View 9 Less Clinical Trials

40 Total Publications

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.
Journal: Research square
Published: December 03, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (6.8 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist practicing medicine in New York, New York. Dr. Rimner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Thymectomy.

Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (6.8 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist practicing medicine in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (6.8 miles away)
929-459-8263
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joachim Yahalom is a Radiation Oncologist practicing medicine in New York, New York. Dr. Yahalom is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Plasmacytoma, and Tissue Biopsy. Dr. Yahalom is currently accepting new patients.

Frequently Asked Questions about Dr. Hani L. Ashamalla

How do I make an appointment with Dr. Hani L. Ashamalla?

You can book an appointment with Dr. Hani L. Ashamalla by calling their office at 347-341-8817. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hani L. Ashamalla a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hani L. Ashamalla is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hani L. Ashamalla specialize in?

While Dr. Hani L. Ashamalla is a Radiation Oncology, they have specific expertise in Lung Cancer, Prostate Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Hani L. Ashamalla participate in research or clinical trials?

Yes. Dr. Hani L. Ashamalla has published 40 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Hani L. Ashamalla's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hani L. Ashamalla accept my insurance?

Dr. Hani L. Ashamalla accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 347-341-8817 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ashamalla's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile